242 related articles for article (PubMed ID: 9415148)
1. Application of antisense technology to therapeutics.
Heidenreich O; Kang SH; Xu X; Nerenberg M
Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
[TBL] [Abstract][Full Text] [Related]
2. Glucose conjugation of anti-HIV-1 oligonucleotides containing unmethylated CpG motifs reduces their immunostimulatory activity.
Reyes-Darias JA; Sánchez-Luque FJ; Morales JC; Pérez-Rentero S; Eritja R; Berzal-Herranz A
Chembiochem; 2015 Mar; 16(4):584-91. PubMed ID: 25683851
[TBL] [Abstract][Full Text] [Related]
3. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV-1 replication by triple-helix-forming phosphorothioate oligonucleotides targeted to the polypurine tract.
Tsukahara S; Suzuki J; Hiratou T; Takai K; Koyanagi Y; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1997 Apr; 233(3):742-7. PubMed ID: 9168925
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes.
Zelphati O; Zon G; Leserman L
Antisense Res Dev; 1993; 3(4):323-38. PubMed ID: 8155974
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 replication by a two-strand system (FTFOs) targeted to the polypurine tract.
Hiratou T; Tsukahara S; Miyano-Kurosaki N; Takai K; Yamamoto N; Takaku H
FEBS Lett; 1999 Jul; 456(1):186-90. PubMed ID: 10452555
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev.
Lund OS; Nielsen JO; Hansen JE
Antiviral Res; 1995 Sep; 28(1):81-91. PubMed ID: 8585762
[TBL] [Abstract][Full Text] [Related]
8. Anti-human immunodeficiency virus type 1 of a two-strand-system targeted to the polypurine tract.
Hiratou T; Miyano-Kurosaki N; Tsukahara S; Tamura Y; Takai K; Yamamoto N; Takaku H
Int J Mol Med; 2000 Feb; 5(2):125-32. PubMed ID: 10639589
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes.
Miyano-Kurosaki N; Barnor JS; Takeuchi H; Owada T; Nakashima H; Yamamoto N; Matsuzaki T; Shimada F; Takaku H
Antivir Chem Chemother; 2004 Mar; 15(2):93-100. PubMed ID: 15185727
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of second-generation antisense oligonucleotides.
Dean NM; Griffey RH
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):229-33. PubMed ID: 9212916
[No Abstract] [Full Text] [Related]
12. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.
Zelphati O; Imbach JL; Signoret N; Zon G; Rayner B; Leserman L
Nucleic Acids Res; 1994 Oct; 22(20):4307-14. PubMed ID: 7524038
[TBL] [Abstract][Full Text] [Related]
13. Oligonucleotides as inhibitors of human immunodeficiency virus.
Field AK
Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
[TBL] [Abstract][Full Text] [Related]
14. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
Zon G
Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
[TBL] [Abstract][Full Text] [Related]
15. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
16. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
Agrawal S; Tang JY
Antisense Res Dev; 1992; 2(4):261-6. PubMed ID: 1363378
[No Abstract] [Full Text] [Related]
17. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system.
Lavigne C; Thierry AR
Biochem Biophys Res Commun; 1997 Aug; 237(3):566-71. PubMed ID: 9299405
[TBL] [Abstract][Full Text] [Related]
18. Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites.
Jakobsen MR; Haasnoot J; Wengel J; Berkhout B; Kjems J
Retrovirology; 2007 Apr; 4():29. PubMed ID: 17459171
[TBL] [Abstract][Full Text] [Related]
19. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.
Agrawal S; Jiang Z; Zhao Q; Shaw D; Cai Q; Roskey A; Channavajjala L; Saxinger C; Zhang R
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2620-5. PubMed ID: 9122245
[TBL] [Abstract][Full Text] [Related]
20. A new class of anti-HIV-1 oligonucleotide targeted to the polypurine tract of viral RNA.
Hiratou T; Miyano-Kurosaki N; Gushima H; Takaku H
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):715-8. PubMed ID: 11563099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
